20/04/2022
So good! 👏🙌🏼
Medtronic welcomes the commitment made by the Coalition and Labor to enable expanded access to publicly funded Continuous Glucose Monitoring (CGM) for all patients with Type 1 Diabetes in Australia from 1 July 2022.
Continuous Glucose Monitoring is an advanced way for people living with diabetes to check glucose levels in real-time or monitor sugar levels over a period of time.
An extension of the CGM program is an important commitment that recognises the value of this technology in helping all patients with Type 1, and their Health Care Professionals, manage their condition. It addresses an access gap to this technology, and ensures those who are eligible under the existing CGM program do not have to revert to finger- pricking.
This announcement is a result of the many voices that advocate for Type 1 patients especially the Juvenile Diabetes Research Foundation, Diabetes Australia and the Australian Diabetes Society.
Medtronic Australasia will work with Government to support the implementation of this important measure.
For more information on Medtronic's diabetes technology, please visit www.medtronic-diabetes.com.au
